Pulmonary hypertension in chronic lung disease and hypoxia
Open accessThe DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index.
Abstract
Pulmonary hypertension (PH) frequently complicates the course of patients with various forms of chronic lung disease (CLD). CLD-associated PH (CLD-PH) is invariably associated with reduced functional ability, impaired quality of life, greater oxygen requirements and an increased risk of mortality. The aetiology of CLD-PH is complex and multifactorial, with differences in the pathogenic sequelae between the diverse forms of CLD. Haemodynamic evaluation of PH severity should be contextualised within the extent of the underlying lung disease, which is best gauged through a combination of physiological and imaging assessment. Who, when, if and how to screen for PH will be addressed in this article, as will the current state of knowledge with regard to the role of treatment with pulmonary vasoactive agents. Although such therapy cannot be endorsed given the current state of findings, future studies in this area are strongly encouraged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The OPTN/UNOS registry data demonstrate that Group 3 pulmonary hypertension is common in patients with advanced CF, ILD, and COPD and is associated with increased oxygen requirements and increased mortality.(294–299)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [294]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence and Outcomes of Pulmonary Arterial Hypertension in Advanced Idiopathic Pulmonary Fibrosis
Lettieri, C. J., Nathan, S. D., Barnett, S. D., Ahmad, S., & Shorr, A. F. (2006) · Chest · doi:10.1378/chest.129.3.746 · Cited by 879
Self-citationSildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
Ghofrani, H. A., Wiedemann, R., Rose, F., Schermuly, R. T., Olschewski, H., Weissmann, N., Gunther, A., Walmrath, D., Seeger, W., & Grimminger, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11024-5 · Cited by 769
Self-citationSevere Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
Chaouat, A., Bugnet, A.-S., Kadaoui, N., Schott, R., Enache, I., Ducoloné, A., Ehrhart, M., Kessler, R., & Weitzenblum, E. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200401-006oc · Cited by 714
Pulmonary Hypertension in Chronic Lung Diseases
Seeger, W., Adir, Y., Barberà, J. A., Champion, H., Coghlan, J. G., Cottin, V., De Marco, T., Galiè, N., Ghio, S., Gibbs, S., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.036 · Cited by 673
Self-citationA Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
Consensus Statement on Chronic and Subacute High Altitude Diseases
León-Velarde, F., Maggiorini, M., Reeves, J. T., Aldashev, A., Asmus, I., Bernardi, L., Ge, R.-L., Hackett, P., Kobayashi, T., Moore, L. G., et al. (2005) · High Altitude Medicine & Biology · doi:10.1089/ham.2005.6.147 · Cited by 630
Treatment of Idiopathic Pulmonary Fibrosis With Ambrisentan: A Parallel, Randomized Trial
Raghu, G., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Nathan, S. D., Wells, A. U., Collard, H. R., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-9-201305070-00003 · Cited by 553
Self-citationKESSLER, R., FALLER, M., FOURGAUT, G., MENNECIER, B., & WEITZENBLUM, E. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9803117 · Cited by 549
Obesity-Associated hypoventilation in hospitalized patients: prevalence, effects, and outcome
Nowbar, S., Burkart, K. M., Gonzales, R., Fedorowicz, A., Gozansky, W. S., Gaudio, J. C., Taylor, M. R. G., & Zwillich, C. W. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.08.022 · Cited by 512
Clinical features of paediatric pulmonary hypertension: a registry study
Berger, R. M., Beghetti, M., Humpl, T., Raskob, G. E., Ivy, D. D., Jing, Z.-C., Bonnet, D., Schulze-Neick, I., & Barst, R. J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61621-8 · Cited by 508
Pulmonary Arterial Enlargement and Acute Exacerbations of COPD
Wells, J. M., Washko, G. R., Han, M. K., Abbas, N., Nath, H., Mamary, A. J., Regan, E., Bailey, W. C., Martinez, F. J., Westfall, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203830 · Cited by 499
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome
Cottin, V., Le Pavec, J., Prévot, G., Mal, H., Humbert, M., Simonneau, G., Cordier, J.-F., & GERM“O”P (2010) · European Respiratory Journal · doi:10.1183/09031936.00038709 · Cited by 478
Idiopathic Pulmonary Fibrosis and Emphysema
Mejía, M., Carrillo, G., Rojas-Serrano, J., Estrada, A., Suárez, T., Alonso, D., Barrientos, E., Gaxiola, M., Navarro, C., & Selman, M. (2009) · Chest · doi:10.1378/chest.08-2306 · Cited by 468
Weitzenblum, E., Sautegeau, A., Ehrhart, M., Mammosser, M., & Pelletier, A. (1985) · American Review of Respiratory Disease · doi:10.1164/arrd.1985.131.4.493 · Cited by 461
A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation
The Long-Term Oxygen Treatment Trial Research Group (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604344 · Cited by 428
Pulmonary Hypertension in Patients With Idiopathic Pulmonary Fibrosis
Nadrous, H. F., Pellikka, P. A., Krowka, M. J., Swanson, K. L., Chaowalit, N., Decker, P. A., & Ryu, J. H. (2005) · Chest · doi:10.1378/chest.128.4.2393 · Cited by 427
Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis
Nunes, H. (2005) · Thorax · doi:10.1136/thx.2005.042838 · Cited by 420
Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis
OLSCHEWSKI, H., ARDESCHIR GHOFRANI, H., WALMRATH, D., SCHERMULY, R., TEMMESFELD-WOLLBRÜCK, B., GRIMMINGER, F., & SEEGER, W. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.2.9810008 · Cited by 410
Self-citationHamada, K., Nagai, S., Tanaka, S., Handa, T., Shigematsu, M., Nagao, T., Mishima, M., Kitaichi, M., & Izumi, T. (2007) · Chest · doi:10.1378/chest.06-1466 · Cited by 390
Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant
Shorr, A. F., Wainright, J. L., Cors, C. S., Lettieri, C. J., & Nathan, S. D. (2007) · European Respiratory Journal · doi:10.1183/09031936.00107206 · Cited by 377
Self-citationA randomised, controlled trial of bosentan in severe COPD
Stolz, D., Rasch, H., Linka, A., Di Valentino, M., Meyer, A., Brutsche, M., & Tamm, M. (2008) · European Respiratory Journal · doi:10.1183/09031936.00011308 · Cited by 356
Hemodynamic Response to Oxygen Therapy in Chronic Obstructive Pulmonary Disease
TIMMS, R. M., KHAJA, F. U., & WILLIAMS, G. W. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-102-1-29 · Cited by 341
Ghofrani, H. A., Reichenberger, F., Kohstall, M. G., Mrosek, E. H., Seeger, T., Olschewski, H., Seeger, W., & Grimminger, F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-3-200408030-00005 · Cited by 309
Self-citationPulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics: Table. 1—
Shorr, A. F., Helman, D. L., Davies, D. B., & Nathan, S. D. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00083404 · Cited by 290
Self-citationBrain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease
Leuchte, H. H., Baumgartner, R. A., Nounou, M. E., Vogeser, M., Neurohr, C., Trautnitz, M., & Behr, J. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1545oc · Cited by 284
Andersen, K. H., Iversen, M., Kjaergaard, J., Mortensen, J., Nielsen-Kudsk, J. E., Bendstrup, E., Videbaek, R., & Carlsen, J. (2012) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2011.11.020 · Cited by 267
Pulmonary hypertension in COPD: results from the ASPIRE registry
Hurdman, J., Condliffe, R., Elliot, C. A., Swift, A., Rajaram, S., Davies, C., Hill, C., Hamilton, N., Armstrong, I. J., Billings, C., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00079512 · Cited by 262
Severe Pulmonary Hypertension in Histiocytosis X
FARTOUKH, M., HUMBERT, M., CAPRON, F., MAÎTRE, S., PARENT, F., LE GALL, C., SITBON, O., HERVÉ, P., DUROUX, P., & SIMONNEAU, G. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.1.9807024 · Cited by 248
Nathan, S. D., Shlobin, O. A., Barnett, S. D., Saggar, R., Belperio, J. A., Ross, D. J., Ahmad, S., Saggar, R., Libre, E., Lynch, J. P., et al. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.03.022 · Cited by 238
Self-citationHan, M. K., Bach, D. S., Hagan, P. G., Yow, E., Flaherty, K. R., Toews, G. B., Anstrom, K. J., & Martinez, F. J. (2013) · Chest · doi:10.1378/chest.12-1594 · Cited by 227
Greiner, S., Jud, A., Aurich, M., Hess, A., Hilbel, T., Hardt, S., Katus, H. A., & Mereles, D. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001103 · Cited by 226
Bosentan in Pulmonary Hypertension Associated with Fibrotic Idiopathic Interstitial Pneumonia
Corte, T. J., Keir, G. J., Dimopoulos, K., Howard, L., Corris, P. A., Parfitt, L., Foley, C., Yanez-Lopez, M., Babalis, D., Marino, P., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0446oc · Cited by 226
Kimura, M., Taniguchi, H., Kondoh, Y., Kimura, T., Kataoka, K., Nishiyama, O., Aso, H., Sakamoto, K., & Hasegawa, Y. (2013) · Respiration · doi:10.1159/000345221 · Cited by 222
Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial
Blanco, I., Santos, S., Gea, J., Güell, R., Torres, F., Gimeno-Santos, E., Rodriguez, D. A., Vilaró, J., Gómez, B., Roca, J., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00176312 · Cited by 185
Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis
Judge, E. P., Fabre, A., Adamali, H. I., & Egan, J. J. (2012) · European Respiratory Journal · doi:10.1183/09031936.00115511 · Cited by 181
Oxygen therapy for interstitial lung disease: a systematic review
Bell, E. C., Cox, N. S., Goh, N., Glaspole, I., Westall, G. P., Watson, A., & Holland, A. E. (2017) · European Respiratory Review · doi:10.1183/16000617.0080-2016 · Cited by 181
Pathophysiology and Treatment of High-Altitude Pulmonary Vascular Disease
Wilkins, M. R., Ghofrani, H. A., Weißmann, N., Aldashev, A. A., & Zhao, L. (2015) · Circulation · doi:10.1161/circulationaha.114.006977 · Cited by 176
Comorbid Conditions and Outcomes in Patients With Pulmonary Arterial Hypertension
Poms, A. D., Turner, M., Farber, H. W., Meltzer, L. A., & McGoon, M. D. (2013) · Chest · doi:10.1378/chest.11-3241 · Cited by 163
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction
Raghu, G., Nathan, S. D., Behr, J., Brown, K. K., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martinez, F. J., Wells, A. U., Shao, L., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01537-2014 · Cited by 163
Self-citationTreatment of Sarcoidosis-Associated Pulmonary Hypertension
Barnett, C. F., Bonura, E. J., Nathan, S. D., Ahmad, S., Shlobin, O. A., Osei, K., Zaiman, A. L., Hassoun, P. M., Moller, D. R., Barnett, S. D., et al. (2009) · Chest · doi:10.1378/chest.08-1881 · Cited by 161
Self-citationBosentan for Sarcoidosis-Associated Pulmonary Hypertension
Baughman, R. P., Culver, D. A., Cordova, F. C., Padilla, M., Gibson, K. F., Lower, E. E., & Engel, P. J. (2014) · Chest · doi:10.1378/chest.13-1766 · Cited by 160
Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension
Boucly, A., Cottin, V., Nunès, H., Jaïs, X., Tazi, A., Prévôt, G., Reynaud‐Gaubert, M., Dromer, C., Viacroze, C., Horeau-Langlard, D., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00465-2017 · Cited by 159
Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial
Hoeper, M. M., Halank, M., Wilkens, H., Günther, A., Weimann, G., Gebert, I., Leuchte, H. H., & Behr, J. (2012) · European Respiratory Journal · doi:10.1183/09031936.00213911 · Cited by 151
Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease
Valerio, G., Bracciale, P., & D'Agostino, A. G. (2009) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808103499 · Cited by 147
Ventilatory and Cardiocirculatory Exercise Profiles in COPD
Boerrigter, B. G., Bogaard, H. J., Trip, P., Groepenhoff, H., Rietema, H., Holverda, S., Boonstra, A., Postmus, P. E., Westerhof, N., & Noordegraaf, A. V. (2012) · CHEST Journal · doi:10.1378/chest.11-2798 · Cited by 145
Goudie, A. R., Lipworth, B. J., Hopkinson, P., Wei, L., & Struthers, A. D. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70013-x · Cited by 143
Vitulo, P., Stanziola, A. A., Confalonieri, M., Libertucci, D., Oggionni, T., Rottoli, P., Paciocco, G., Tuzzolino, F., Martino, L., Beretta, M., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.04.010 · Cited by 143
Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease
Barberà, J. A., & Blanco, I. (2009) · Drugs · doi:10.2165/00003495-200969090-00002 · Cited by 132
Non-invasive ventilation in obesity hypoventilation syndrome without severe obstructive sleep apnoea
Masa, J. F., Corral, J., Caballero‐Eraso, C., Barrot, E., Téran‐Santos, J., Alonso-Álvarez, M. L., Gómez‐García, T., González, M., López-Martín, S., de Lucas, P., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2016-208501 · Cited by 131
Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias
Hoeper, M. M., Behr, J., Held, M., Grünig, E., Vizza, C. D., Noordegraaf, A. V., Lange, T. J., Claussen, M., Grohé, C., Klose, H. F. E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141911 · Cited by 124
Self-citationPulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension
Pavec, J. L., Lorillon, G., Jaïs, X., Tchérakian, C., Feuillet, S., Dorfmüller, P., Simonneau, G., Humbert, M. J. C., & Tazi, A. (2012) · CHEST Journal · doi:10.1378/chest.11-2490 · Cited by 124
Inhaled iloprost for sarcoidosis associated pulmonary hypertension.
Baughman, R. P., Judson, M. A., Lower, E. E., Highland, K. B., Kwon, S. W., Craft, N., & Engel, P. J. (2009) · PubMed · Cited by 115
Held, M., Walthelm, J., Baron, S., Roth, C., & Jany, B. (2013) · European Respiratory Journal · doi:10.1183/09031936.00147712 · Cited by 113
Ambrisentan for sarcoidosis associated pulmonary hypertension.
Judson, M. A., Highland, K. B., Kwon, S., Donohue, J. F., Aris, R. M., Craft, N., Burt, S., & Ford, H. J. (2011) · PubMed · Cited by 112
Alhamad, E. H., Al-Boukai, A. A., Al-Kassimi, F. A., AlFaleh, H., Alshamiri, M. Q., Alzeer, A. H., Al-Otair, H. A., Ibrahim, G. F., & Shaik, S. A. (2011) · Radiology · doi:10.1148/radiol.11103532 · Cited by 112
Pullamsetti, S. S., Kojonazarov, B. K., Storn, S., Gall, H. J., Salazar, Y., Wolf, J., Weigert, A., El-Nikhely, N. A., Ghofrani, H. A., Krombach, G. A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai9048 · Cited by 109
Self-citationPhosphodiesterase type 5 and high altitude pulmonary hypertension
Aldashev, A. A., Kojonazarov, B. K., Amatov, T. A., Sooronbaev, T. M., Mirrakhimov, M. M., Morrell, N. W., Wharton, J., & Wilkins, M. R. (2005) · Thorax · doi:10.1136/thx.2005.041954 · Cited by 105
Sildenafil for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Trial
Lederer, D. J., Bartels, M. N., Schluger, N. W., Brogan, F., Jellen, P. A., Thomashow, B. M., & Kawut, S. M. (2012) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2011.651180 · Cited by 103
High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management
Mirrakhimov, A. E., & Strohl, K. P. (2016) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401610010019 · Cited by 97
Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients
Cottin, V., Harari, S. A., Humbert, M. J. C., Mal, H., Dorfmüller, P., Jaïs, X., Reynaud‐Gaubert, M., Prévôt, G., Lazor, R., Taillé, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00093111 · Cited by 95
Self-citationA haemodynamic study of pulmonary hypertension in chronic hypersensitivity pneumonitis
Oliveira, R. K. F., Pereira, C. A. C., Ramos, R. P., Ferreira, E. V. M., Messina, C. M. S., Kuranishi, L. T., Gimenez, A., Campos, O., Silva, C. C., & Arakaki, J. S. O. (2014) · European Respiratory Journal · doi:10.1183/09031936.00010414 · Cited by 91
Saggar, R., Khanna, D., Vaidya, A., Derhovanessian, A., Maranian, P., Duffy, E. L., Belperio, J. A., Weigt, S. S., Dua, S., Shapiro, S., et al. (2014) · Thorax · doi:10.1136/thoraxjnl-2013-204150 · Cited by 82
Haemodynamic effects of non‐invasive ventilation in patients with obesity‐hypoventilation syndrome
Castro‐Añón, O., Golpe, R., Pérez‐de‐Llano, L. A., González, M. J. L., VELASQUEZ, E. J. E., FERNÁNDEZ, R. P., Testa-Fernández, A. M., & González‐Quintela, A. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02252.x · Cited by 80
Singh, S., Singh, V. P., Rao, R. S., Sharma, B. B., & Agarwal, V. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-53-2-81 · Cited by 80
Prins, K. W., Duval, S., Markowitz, J., PRITZKER, M. R., & Thenappan, T. (2016) · Pulmonary Circulation · doi:10.1086/690017 · Cited by 80
Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis
Launay, D., Montani, D., Hassoun, P. M., Cottin, V., Pavec, J. L., Clerson, P., Sitbon, O., Jaïs, X., Savale, L., Weatherald, J. C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197112 · Cited by 78
Box, P. (2011) · International Journal of Medical Radiology · Cited by 75
Baughman, R. P., Shlobin, O. A., Wells, A. U., Alhamad, E. H., Culver, D. A., Barney, J. B., CORDOVA, F. C., Carmona, E. M., Scholand, M. B., Wijsenbeek, M. S., et al. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.04.015 · Cited by 75
Self-citationSchönhofer, B., Barchfeld, T., Wenzel, M., & Köhler, D. (2001) · Thorax · doi:10.1136/thorax.56.7.524 · Cited by 74
Prostacyclin and Oral Vasodilator Therapy in Sarcoidosis-Associated Pulmonary Hypertension
Bonham, C. A., Oldham, J. M., Gomberg‐Maitland, M., & Vij, R. (2015) · CHEST Journal · doi:10.1378/chest.14-2546 · Cited by 72
Keir, G. J., Walsh, S. L. F., Gatzoulis, M. Α., Marino, P. S., Dimopoulos, K., Alonso-González, R., Raposeiras‐Roubín, S., Renzoni, E. A., Maher, T. M., Wells, A. U., et al. (2014) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 70
Yagi, M., Taniguchi, H., Kondoh, Y., Ando, M., Kimura, T., Kataoka, K., Furukawa, T., Suzuki, A., Johkoh, T., & Hasegawa, Y. (2017) · Respirology · doi:10.1111/resp.13066 · Cited by 68
Mura, M., Anraku, M., Yun, Z., McRae, K. M., Liu, M., Waddell, T. K., Singer, L. G., Granton, J. T., Keshavjee, S. H., & de Perrot, M. E. (2011) · CHEST Journal · doi:10.1378/chest.11-0449 · Cited by 67
Hayes, D., Black, S. M., Tobias, J. D., Kirkby, S., Mansour, H. M., & Whitson, B. A. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.06.024 · Cited by 66
Medrek, S. K., Sharafkhaneh, A., Spiegelman, A. M., Kak, A., & Pandit, L. M. (2017) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412555.2017.1336209 · Cited by 61
Microarray analysis in pulmonary hypertension
Hoffmann, J., Wilhelm, J., Olschewski, A., & Kwapiszewska, G. (2016) · European Respiratory Journal · doi:10.1183/13993003.02030-2015 · Cited by 58
Tanabe, N., Taniguchi, H., Tsujino, I., Sakamaki, F., Emoto, N., Kimura, H., Takamura, K., Hanaoka, M., Nishimura, M., Tatsumi, K., et al. (2015) · Respirology · doi:10.1111/resp.12530 · Cited by 55
Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis
Blanco, I., Ribas, J., Xaubet, A., Gómez, F. P., Roca, J., Rodriguez‐Roisin, R., & Barberà, J. A. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01104.2010 · Cited by 54
Effects of fasudil in patients with high-altitude pulmonary hypertension: Table 1–
Kojonazarov, B. K., Myrzaakhmatova, A. K., Sooronbaev, T., Ishizaki, T., & Aldashev, A. A. (2012) · European Respiratory Journal · doi:10.1183/09031936.00095211 · Cited by 53
Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis
Alkukhun, L., Wang, X.-F., Ahmed, M., Baumgartner, M., Budev, M. M., Dweik, R. A., & Tonelli, A. R. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.06.001 · Cited by 52
D’Andrea, A., Stanziola, A. A., Palma, E. D., Martino, M., D’Alto, M., Dellegrottaglie, S., Cocchia, R., Riegler, L., Cordido, M. V. B., Lanza, M., et al. (2015) · Echocardiography · doi:10.1111/echo.12992 · Cited by 51
Furukawa, T., Kondoh, Y., Taniguchi, H., Yagi, M., Matsuda, T., Kimura, T., Kataoka, K., Johkoh, T., Ando, M., Hashimoto, N., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01311-2017 · Cited by 45
Chen, X., Tang, S., Liu, K., Li, Q., Kong, H., Zeng, X., Xie, W., & Wang, H. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.02.08 · Cited by 44
Gläser, S., Obst, A., Koch, B., Henkel, B., Grieger, A., Felix, S. B., Halank, M., Bruch, L., Bollmann, T., Warnke, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065643 · Cited by 42
Călcăianu, G., Canuet, M., Schuller, A., Enache, I., Chaouat, A., & Kessler, R. (2015) · Respiration · doi:10.1159/000441304 · Cited by 38
Nowak, J. U., Hudzik, B., Jastrzębski, D., Niedziela, J. T., Rozentryt, P., Wojarski, J., Ochman, M., Karolak, W., Żegleń, S., Gierlotka, M. J., et al. (2017) · The Clinical Respiratory Journal · doi:10.1111/crj.12608 · Cited by 37
Xu, Y., Liu, Y., Liu, J., & Qian, G. (2014) · High Altitude Medicine & Biology · doi:10.1089/ham.2013.1110 · Cited by 34
Outcome of Patients with Severe PH due to Lung Disease with and without Targeted Therapy
Lange, T. J., Baron, M., Seiler, I., Arzt, M. E., & Pfeifer, M. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12084 · Cited by 28
Manika, Κ., Pitsiou, G., Boutou, A., Tsaoussis, V., Chavouzis, N., Antoniou, M., Fotoulaki, M., Stanopoulos, I., & Kioumis, I. P. (2012) · Pulmonary Medicine · doi:10.1155/2012/252345 · Cited by 27
Teramachi, R., Taniguchi, H., Kondoh, Y., Ando, M., Kimura, T., Kataoka, K., Suzuki, A., Furukawa, T., Sakamoto, K., & Hasegawa, Y. (2017) · Respirology · doi:10.1111/resp.12986 · Cited by 25
Nathan, S. D., Behr, J., Collard, H. R., Cottin, V., Hoeper, M. M., Martínez, F. J., Corte, T. J., KEOGH, A. M., Leuchte, H. H., Moğulkoç, N., et al. (2017) · European Respiratory Journal · doi:10.1183/1393003.congress-2017.oa1985 · Cited by 25
Self-citationPark, J., Song, J. H., Park, D. A., Lee, J. S., Lee, S., & Oh, Y. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.8.1200 · Cited by 22
NİAZOVA, Z., Ta, B., Aikimbaev, K. S., Kudaiberdieva, G. Z., Akgül, F., Soodanbekova, Y. K., & Birand, A. (1996) · PubMed · Cited by 16
Cited by
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citationHaemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Self-citationLeard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
An overview of the 6th World Symposium on Pulmonary Hypertension
Galiè, N., McLaughlin, V. V., Rubin, L. J., & Simonneau, G. (2019) · European Respiratory Journal · doi:10.1183/13993003.02148-2018 · Cited by 526
Metadata
- Authors
- Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., Weissmann, N., & Seeger, W.
- Affiliations
- Inova Fairfax Hospital (US)
- MultiMedica (IT)
- Medical University of Graz (AT)
- Medizinische Hochschule Hannover (DE)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Justus-Liebig-Universität Gießen (DE)
- ORCID
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-01
- Volume
- 53
- Issue
- 1
- Pages
- 1801914
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC6351338
- OpenAlex
- W2904463477
- Cited by
- 757
- References
- 94
- Citations by year
- 2026: 54 · 2025: 104 · 2024: 141 · 2023: 96 · 2022: 122 · 2021: 114 · 2020: 76 · 2019: 44
- FWCI
- 10.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Journal (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, cc-by-nc)
- Funders
- American Thoracic Society
- Pfizer
- AstraZeneca
- Bayer
- GlaxoSmithKline
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- United Therapeutics Corporation
- Sunovion
- Veracyte
- York University
- National Institutes of Health
- Genentech
- Actelion Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- pulmonary hypertension, chronic lung disease, hypoxia, hemodynamic assessment, quality of life, mortality risk, oxygen requirement
- MeSH terms
- Animals, Hypoxia, Antihypertensive Agents, Chronic Disease, Humans, Hypertension, Pulmonary, Lung Diseases, Interstitial, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.